As is known, HIV antibody has already been a debated issue around the whole world. In recent days, a group of scientists from the US National Institutes of Health (NIH) discovered a new vulnerability on HIV therapy armor, which could be exploited by vaccine or other preventive programs. This special loci has crossed two proteins of viral envelope, namely the gp41 and gp120; it has added a broadly neutralized antibody on the new HIV binding site as well.
Generally speaking, AIDS is caused by HIV, which could destroy human body’s immune system. Thus, such patients can lose the ability to resist a variety of pathogens and then lead to the occurrence of various kinds of infections or tumors. Clearly, death is always the ultimate result for AIDS. Official data from the United Nations have shown a fact that more than 34 million people around the world have been infected with HIV virus or suffered from AIDS. More specifically, the vast majority occur in low- and middle-income countries such as Africa. Nowadays, AIDS has become the number one infectious killer and so far the disease has killed more than 3,000 people.
So how to improve such dilemma? In fact, a new and efficient HIV antibody has been discovered which I believe will help improve the problem. Technically, this new HIV antibody can be significant in inducing a way to identify the strong neutralizing antibody response of HIV strains with high diversity. Since the unique antigenic variation of glycoproteins appears on Env’s surface, the research on HIV vaccine is certainly a considerable challenge. Recently, scientists have discovered a new antibody on the virus site from a HIV-infected patient; it is referred as 35O22 antibody, which can resist 62 percent of known HIV strains from getting infected with the laboratory cells; it’s very effective.
Based on the discovery, relatively small number of 35O22 antibody can neutralize the virus. In addition, the new antibody can help the scientists on drug research to a large degree. However, some researchers also said there might be a new combination of the vulnerabilities, so an important complement to the current monoclonal antibody therapy is required. To be brief, the vaccine used in HIV might be helpful in producing a new efficient antibody, and an increasing number of efforts should be done to discover more available antibodies that can neutralize the HIV strains.